Evidence map›Paper›PMID 33891265›Full record

ArticleMolecular imaging and biology2021

Monitoring PSMA Responses to ADT in Prostate Cancer Patient-Derived Xenograft Mouse Models Using [

Jyoti Roy, Margaret E White, Falguni Basuli, Ana Christina L Opina, Karen Wong, Morgan Riba, Anita T Ton, Xiang Zhang, Keith H Jansson, Elijah Edmondson and 5 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular imaging and biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Trial
  2. Distinct prognostic value of [Communications medicine · 2026
    Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Enzalutamide Enhances PSMA Expression of PSMA-Low Prostate Cancer.International journal of molecular sciences · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 1 country.

Jyoti RoyMolecular Imaging Program, NCI/NIH, Center for Cancer Research, National Cancer Institute, Building 10, Room B3B406, Bethesda, MD, 20892, USA.
Margaret E WhiteLaboratory of Genitourinary Cancer Pathogenesis NCI/NIH, Bethesda, MD, USA.
Falguni BasuliChemistry and Synthesis Center, NHLBI/NIH, Rockville, MD, USA.
Ana Christina L OpinaChemistry and Synthesis Center, NHLBI/NIH, Rockville, MD, USA.
Karen WongMolecular Imaging Program, NCI/NIH, Center for Cancer Research, National Cancer Institute, Building 10, Room B3B406, Bethesda, MD, 20892, USA.
Morgan RibaLaboratory of Genitourinary Cancer Pathogenesis NCI/NIH, Bethesda, MD, USA.
Anita T TonMolecular Imaging Program, NCI/NIH, Center for Cancer Research, National Cancer Institute, Building 10, Room B3B406, Bethesda, MD, 20892, USA.
Xiang ZhangChemistry and Synthesis Center, NHLBI/NIH, Rockville, MD, USA.
Keith H JanssonLaboratory of Genitourinary Cancer Pathogenesis NCI/NIH, Bethesda, MD, USA.
Elijah EdmondsonPathology/Histotechnology Laboratory, Leidos, Inc./Frederick National Laboratory for Cancer Research, NCI, Frederick, MD, USA.
Donna ButcherPathology/Histotechnology Laboratory, Leidos, Inc./Frederick National Laboratory for Cancer Research, NCI, Frederick, MD, USA.
Frank I LinMolecular Imaging Program, NCI/NIH, Center for Cancer Research, National Cancer Institute, Building 10, Room B3B406, Bethesda, MD, 20892, USA.
Peter L ChoykeMolecular Imaging Program, NCI/NIH, Center for Cancer Research, National Cancer Institute, Building 10, Room B3B406, Bethesda, MD, 20892, USA.
Kathleen KellyLaboratory of Genitourinary Cancer Pathogenesis NCI/NIH, Bethesda, MD, USA.
Elaine M JagodaMolecular Imaging Program, NCI/NIH, Center for Cancer Research, National Cancer Institute, Building 10, Room B3B406, Bethesda, MD, 20892, USA. ejagoda@mail.nih.gov.ORCID 0000-0001-8455-9634
National Cancer Institute · USNational Socio-Environmental Synthesis Center · USLeidos (United States) · US

Funding

Mechanisms of pathogenesis in patient derived organoid models of prostate cancerZIABC011782 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI KELLY, KATHLEEN · 2017 to 2024
$8.2M
Prostate Cancer ImagingZ01BC010655 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI CHOYKE, PETER L · 2005 to 2008
$2.1M
Identifying genetic vulnerabilities in neuroendocrine prostate cancerZIABC011919 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI KELLY, KATHLEEN · 2019 to 2024
$1.4M
Improving PSMA-based radioligand therapy via combination radioligand therapyZIABC011895 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI LIN, FRANK · 2019 to 2025
$1.1M
Intramural NIH HHS Z01 BC010655Intramural NIH HHS ZIA BC011782Intramural NIH HHS ZIA BC011895
6 · The paper itself

Abstract

purposePSMA overexpression has been associated with aggressive prostate cancer (PCa). However, PSMA PET imaging has revealed highly variable changes in PSMA expression in response to ADT treatment ranging from increases to moderate decreases. To better understand these PSMA responses and potential relationship to progressive PCa, the PET imaging agent, [

methods[

results[

conclusionTumor responses to ADT varied from sensitive to resistant among these LuCaP PDXs, while only the high PSMA expressing LuCaP model exhibited an increase in PSMA levels in response to ADT. These models may be useful in understanding the clinical relevance of PSMA PET responses to ADT and potentially the relationship to disease progression as it may relate to the genomic signature.

Indexed as

Prostate-Specific AntigenProstatic NeoplasmsAndrogen AntagonistsAnimalsAntineoplastic Agents, HormonalCell Line, TumorDisease Models, AnimalHumansLysineMaleMicePositron-Emission TomographyUreaXenograft Model Antitumor Assays2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acidAndrogen AntagonistsAntineoplastic Agents, HormonalLysineProstate-Specific AntigenUreaADT therapyAndrogen deprivation therapyLuCaPPDXPET imagingProstate cancerPSMA

Identifiers

PMID33891265
PMCPMC9910584
OpenAlexW3155737669

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.